---
title: "Optimizing Variations Management Under the New EU Guideline"
description: "This webinar moves beyond the published text of the new EU Variations Guideline into its day-to-day reality, tackling the frictions Regulatory Affairs teams face today, built on real post-implementation experience."
url: https://qbdgroup.com/en/webinars/optimizing-variations-management-new-eu-guideline
type: "Webinar"
language: en
published: 2026-10-06
author: "QbD Group"
category: "Regulatory Affairs"
publisher: "QbD Group"
citation: "QbD Group, \"Optimizing Variations Management Under the New EU Guideline\", https://qbdgroup.com/en/webinars/optimizing-variations-management-new-eu-guideline"
---
# Optimizing Variations Management Under the New EU Guideline
> This webinar moves beyond the published text of the new EU Variations Guideline into its day-to-day reality, tackling the frictions Regulatory Affairs teams face today, built on real post-implementation experience.

_Smarter grouping, work-sharing, and portfolio-level reporting to cut cost and complexity_

🕐 3 PM CET

## Introduction

When the new EU Variations Guideline came into application on 15 January 2026, it was positioned as a long-awaited simplification of the post-authorization change framework: clearer classification chapters, more predictable procedures, and better alignment across Member States.

Several months into its application, the picture on the ground is more mixed. Some processes have genuinely become clearer. Others have simply moved the friction somewhere else: reclassifications, diverging national interpretations, work-sharing procedures that don't always behave as expected, and reporting requirements teams are still adapting to.

## About the webinar

Most of the content published around the new Variations Guideline focused on explaining what the text says. This session takes a different approach: it looks at **what has actually happened** since organizations started applying it.

Drawing on real post-implementation experience, we examine where the new framework is working as intended, where there's still room to mature, and what that means in practical terms (workload, timelines, and resource allocation) for Regulatory Affairs teams managing variations day to day.

The session will also make the case that many of the frictions attributed to "the new guideline" are, in fact, older problems in variations management that the new framework has simply made more visible: poor grouping strategies, lack of portfolio-level visibility, and reactive rather than planned handling of change.

We will conclude by looking at how organizations can move from treating variations as a recurring compliance task to managing them as a **structured, plannable part of [Lifecycle Management](https://qbdgroup.com/en/industries/pharma-biotech/life-cycle-management)**, regardless of which version of the guideline is in force.

## What You'll Learn

- What has genuinely changed in the classification and procedural handling of variations since 15 January 2026, based on real submissions rather than the published text alone
- Which of these friction points aren't new (work-sharing, national divergence, grouping strategy, portfolio visibility) but are now more visible because of the new guideline
- How these pain points translate into real cost (lost time, delayed launches, resourcing gaps) and practical tips to reduce it
- Practical criteria for deciding when a variation should be grouped, escalated, or planned differently to avoid downstream delays
- How to move variations management from a reactive, transaction-by-transaction activity to a planned, portfolio-level function

## Speakers

### Joanna Rapacz

**Business Unit Manager CMC & RA, QP | CMC & RA Director · QbD Group**

![Joanna Rapacz](https://jrtdedcfhvzaomneervp.supabase.co/storage/v1/object/public/avatars/joanna-rapacz-2.png)

Joanna brings over 25 years of pharmaceutical industry experience to her role as RA & CMC Director and Qualified Person at QbD Group. Her expertise spans Regulatory Affairs, CMC strategy, GMP quality oversight, and compliance implementation, underpinned by a strong foundation in quality control and R&D. She supports pharmaceutical organizations across the full scope of development and international product authorization.

### Katarzyna Piskorska-Małolepsza

**PhD, Senior Consultant RA | Team Lead · QbD Group**

![Katarzyna Piskorska-Małolepsza](https://jrtdedcfhvzaomneervp.supabase.co/storage/v1/object/public/avatars/katarzyna-piskorska-malolepsza.png)

Katarzyna is a Regulatory Affairs Expert at QbD Group with 10 years of experience in the pharmaceutical industry. Her background covers CMC strategy, Regulatory Affairs, GMP, and compliance implementation, built through hands-on work with development programs and international product authorization across diverse markets.

## Who Should Attend

- Heads, Directors, and Managers of Regulatory Affairs
- Regulatory Affairs professionals managing variations, submissions, renewals, and post-approval activities
- Lifecycle Management and CMC professionals involved in change control and portfolio planning
- Quality and Compliance professionals overseeing post-authorization change processes
- Procurement and outsourcing managers evaluating regulatory operating models and external support
---
Source: https://qbdgroup.com/en/webinars/optimizing-variations-management-new-eu-guideline — © QbD Group. Quote freely with attribution and a link back.